Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SAMe Benefits For Depression, Osteoarthritis, Liver Disease Noted By AHRQ

This article was originally published in The Tan Sheet

Executive Summary

Dose escalation and risk benefit studies of SAMe for treatment of depression, osteoarthritis and liver disease are among the "promising" areas of future research involving the supplement ingredient identified by the Agency for Healthcare Research & Quality

You may also be interested in...

ODS Evidence-Based Review Program Recruits NCI Official

The National Institutes of Health's Office of Dietary Supplements will help stimulate and prioritize supplement research by commissioning several evidence-based reviews from the Agency for Healthcare Research & Quality

AHRQ Ephedra Evidence Report Targeted For August 2002 Release

An Agency for Healthcare Research & Quality report on the safety and efficacy of ephedra, commissioned by the National Institutes of Health, could be released as early as August 2002.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts